Bridgebio Pharma, Inc.NASDAQ: BBIO

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

Mar 30, 2026 · Issued by Bridgebio Pharma, Inc.

- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p